Brief: Sagimet Biosciences reports fourth-quarter net loss of $16.2 mln
12/03/2025 11:35
March 12 (Reuters) - Sagimet Biosciences Inc SGMT.O: SAGIMET BIOSCIENCES Q4 NET INCOME USD -16.201 MILLION SAGIMET BIOSCIENCES INC - DENIFANSTAT PHASE 3 MASH PROGRAM INITIATED, PATIENT SCREENING IN 1H 2025 Source text: nGNX8D4Hx6 Further company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage